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Abstract
The mitochondrial matrix GTPase NOA1 is a nuclear encoded protein, essential for mitochondrial protein synthesis, oxidative
phosphorylation and ATP production. Here, we demonstrate that newly translated NOA1 protein is imported into the
nucleus, where it localizes to the nucleolus and interacts with UBF1 before nuclear export and import into mitochondria.
Mutation of the nuclear localization signal (NLS) prevented both nuclear and mitochondrial import while deletion of the N-
terminal mitochondrial targeting sequence (MTS) or the C-terminal RNA binding domain of NOA1 impaired mitochondrial
import. Absence of the MTS resulted in accumulation of NOA1 in the nucleus and increased caspase-dependent apoptosis.
We also found that export of NOA1 from the nucleus requires a leptomycin-B sensitive, Crm1-dependent nuclear export
signal (NES). Finally, we show that NOA1 is a new substrate of the mitochondrial matrix protease complex ClpXP. Our results
uncovered an unexpected, mandatory detour of NOA1 through the nucleolus before uptake into mitochondria. We propose
that nucleo-mitochondrial translocation of proteins is more widespread than previously anticipated providing additional
means to control protein bioavailability as well as cellular communication between both compartments.
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Introduction
Mitochondrial function is crucial for energy production and
cellular survival. Maintain and adaption of mitochondrial func-
tions to changing cellular needs is accomplished by complex
signaling networks regulating mitochondrial effector proteins on
the transcriptional or post-translational level. The majority of
mitochondrial proteins is encoded in the nucleus and post-
translationally imported into the mitochondrial membranes or into
the matrix. Typical mitochondrial matrix proteins contain a N-
terminal signaling peptide.
The NOA1 protein is a nuclear encoded mitochondrial matrix
GTPase that stimulated OXPHOS activity [1–3]_ENREF_2_EN-
REF_5. Knockout studies revealed that NOA1 regulates mito-
chondrial protein biosynthesis by influencing mitochondrial
ribosome biogenesis [4], which was also confirmed by studies on
the bacterial NOA1 homolog YqeH [5,6]_ENREF_7. Most likely,
NOA1 is involved in additional cellular processes as indicated by
recent reports indicating binding and potentially transport of G-
quadruplex RNA or protection of cells from staurosporine induced
apoptosis following knockdown [7]. Although the full range of
biological activities of NOA1 still needs to be uncovered, it is clear
that NOA1 is an essential mitochondrial matrix GTPase that acts
as a limiting factor for mitochondrial protein synthesis and ATP
production by oxidative phosphorylation.
Previous work on NOA1’s function mostly concentrated on the
mitochondrial localization and function. However, the NOA1
amino acid sequence contains a classical bipartite nuclear
localization signal (NLS) suggesting that NOA1 also localizes to
the nucleus. In fact, other proteins have been described that are
localized in different cellular compartments. Such proteins might
be produced as distinct isoforms, carry ambiguous targeting signals
(e.g. for chloroplast and mitochondria) or contain two competing
targeting signals [8,9]. The activity of competing targeting signals
most often depends on accessibility of signals, which might be
regulated by ligand binding, protein-protein interactions [10] or
posttranslational modifications affecting receptor interactions
[11,12]. In eukaryotes, several proteins are targeted both to
chloroplast and mitochondria (in plants), to organelles and cytosol
or to mitochondria and the ER. Examples of nucleo-mitochondrial
proteins are less abundant. LRPPRC [13,14], a pentatricopeptide
repeat containing protein involved in the pathogenesis of human
diseases [15,16], is located in the nucleus and mitochondria. In the
nucleus, LRPPRC is part of a ribonucleoprotein complex
responsible for the nuclear export of mRNAs [17]. In mitochon-
dria, LRPPRC is required for polyadenylation and translation of
mitochondrial mRNAs [18]. The ELAC2 protein, responsible for
RNaseZ activity, is also found in both mitochondria and the
nucleus [19]. Furthermore, TERT, the catalytic subunit of
telomerase, is imported into mitochondria during oxidative stress
to protect the mitochondrial genome [20]. Finally, p53 has been
shown to localize to mitochondria during cellular stress [21].
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Here, we studied potential cellular transport routes of NOA1,
which led to the discovery of a mandatory nuclear shuttling
pathway relying on specific nuclear import and export signals
prior to transport into mitochondria. Our results revealed that
nuclear accumulation of NOA1 activates apoptosis indicating the
need for tight control of NOA1 protein concentrations. To gain
further insights into the pathways controlling NOA1 levels we
searched for enzymes degrading NOA1 and found that NOA1 is a
new substrate of matrix protease ClpXP. We reason that the initial
localization of NOA1 in the nucleus is essential for its mitochon-
drial function and propose that NOA1 is the founding member of
a new class of nucleo-mitochondrial proteins.
Material and Methods
Molecular Cloning
The NOA1 coding sequence (NM_019836) was amplified by
PCR using proofreading high-fidelity Phusion Polymerase (Finn-
zymes). Two enzymatic restriction sites (59-GGA TCC BamH1,
39-CTC GAG SlaI) and a Flag tag (59-GAT TAT AAG GAT
GAT GAT GAT AAG-39) were introduced by primer design.
Truncation variants of NOA1 and the NOA1 NLS-mutant were
produced by PCR using appropriate primer combinations. The
ClpX coding sequence (NM_011802) was amplified from cDNA
derived from C57/Bl6 mouse heart using the following primers:
ClpX forward 59-GGA TCC ATG TCC AGT TGC GGC GCT
TGT-39, ClpX stop reverse 59-CTC GAG TTA GCT GTT TGC
AGC ATC CGC TTG AC-39. A detailed description of the
cloning procedure is given in the supplementary materials.
Cell culture
Mouse myoblast C2C12, fibroblast NIH 3T3, macrophage
RAW264.7 cells and HEK293 cells were cultured at 37uC in
humidified incubators with 8% CO2. All cells were grown in
DMEM (4.5 g glucose, PAA) supplemented with 10% FCS, 1%
penicillin/streptomycin and 1% L-glutamine. Cells were treated
with Flunarizine (100 mM), leptomycin-B (5–20 ng/ml), Cyclo-
heximide (10 ng/ml) or DMSO for the indicated times. Chemicals
were purchased from Sigma Aldrich. Fractionation was performed
with the Proteome Fractionation Kit (Calbiochem) following the
manufacturer’s protocol.
Annexin V and propidium iodide (PI) staining for Flow
cytometry
Phosphatidylserine on the cell surface was detected with
Annexin V-FITC (Sigma). DNA was detected with propidium
iodide (PI), (Sigma). Cells were transfected 8 hours prior staining
with plasmids encoding NOA1 (wild type and DMTS mutant),
incubated with or without 1 mM pan-caspase inhibitor Z-VAD-
FMK (Sigma), detached by incubation in a trypsin/EDTA
solution, washed twice with cold PBS and resuspended in 100 ml
PBS, followed by incubation with 0.25 mg/ml FITC-conjugated
Annexin V and 1 mg/ml PI in PBS for 15 min at room
temperature in the dark. Before flow cytometry (BD LSRII
FACS), cells were washed twice with 1x PBS and resuspended in
500 ml PBS. Data were analyzed using the FACS diva version 6
software.
Western blot analysis
Immunoblotting was performed with whole cell lysates,
fractionated lysates, isolated nuclei or immunoprecipitation
samples using the NuPAGE system according to the manufactur-
er’s recommendations (Invitrogen). For preparation of whole cell
lysates cells were washed with PBS and lysed in Laemmli lysis
buffer (67 mM Tris-HCl pH 6.8, 0.7% SDS). Subcellular
fractionation was performed using the ProteoExtrac Subcellular
Proteome Extraction Kit (Calbiochem) following the manufactur-
er’s protocol. Immunoprecipitations were performed using stan-
dard protocols. The following antibodies were used: anti-penta His
(Qiagen), anti-FlagM2 (Sigma), OXPHOS complex I subunit 39 k
(Invitrogen), anti-S6 ribosomal protein (Cell Signalling), anti-
Tfam, anti-Tom20, anti-Ubf1, anti-Fibrillarin (Santa Cruz Bio-
technology). The Alexafluor 680-conjugated secondary antibodies
from different species were purchased from Invitrogen. The IRD-
800 antibodies were purchased from Rockland. The polyclonal
antibody against NOA1 was raised in rabbits by Eurogentec
(Liege, Belgium) and detects specifically precursor and mature
NOA1 protein (Figure S1 in File S1).
Immunochemistry
Cells were washed with PBS and fixed with 4% paraformalde-
hyde for 10 min. Cells were permeabilized with 0.3% Triton X-
100 in PBS for 10 min and washed with PBS before addition of
the primary antibody and incubation overnight. Cells were stained
for 1 hour with secondary antibody after washing with PBS. DAPI
was applied together with the last wash. NOA1-rabbit polyclonal
antibody was purchased from Eurogentec. The cy3 and cy2-
labeled secondary antibodies were purchased from Dianova. The
Alexafluor 488- and 594-conjugated secondary antibodies were
purchased from Invitrogen. Microscopy was performed with a
Zeiss Z1 microscope with Apotome and a Zeiss Confocal Laser
Scanning Microscope LSM710. Data were analyzed using CLSM
software from Zeiss. Nuclear import assays were established based
on previously published protocols [22,23]. Details are described in
supplementary materials.
Recombinant NOA1-His6 protein
In this study, recombinant mouse NOA1-His6 protein lacking
the mitochondrial targeting sequence (aa 1–17) was used, which
was generated as described before [32].
ClpXP protein purification and in vitro degradation assay
E. coli ClpX was purified as described in [24], E. coli ClpP-His6
[25] and H. sapiens ClpP-His6 were purified as described [26].
The predicted mature form of mouse ClpX (BC061153, aa 66–
634) was expressed from pET28b with N-terminal fusion to
His6SUMO, by induction with 0.5 mM IPTG at 22uC for 4 h in
BL21(DE3) E. coli. Degradation of NOA1 (3 nM) in vitro was
assayed in the presence of 0.3 nM ClpX hexamer, and 0.8 nM
ClpP 14-mer, in 25 mM Hepes pH 7.6, 100 mM KCl, 5 mM
MgCl2, and 10% glycerol using an ATP regenerating system
(5 mM creatine phosphate and 50 mg/mL creatine kinase, 4 mM
ATP). Degradation was performed at 30uC. Samples from
different time points were taken by pipetting aliquots of the
incubation mixture into Laemmli SDS-PAGE loading buffer.
Degradation products were separated by SDS-PAGE, stained with
Sypro Orange, and imaged with a Typhoon scanner (GE
Healthcare).
Results
The NOA1 protein is transported into mitochondria and
the nucleus
The mitochondrial, multi-domain GTPase NOA1 (Fig. 1A)
contains a classical N-terminal mitochondrial targeting sequence
(MTS) that is processed during mitochondrial import resulting in a
shorter mature protein. To analyze the functional relevance of the
potential MTS we deleted the first 17 amino acids of the NOA1
NOA1 Requires Nuclear Shuttling
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precursor protein. Deletion of the MTS prevented processing of
NOA1 as indicated by the presence of a single band in Western
blot analysis after transfection of NOA1DMTS (Fig. 1B). In silico
analysis (cNLS mapper [27]) predicted a classical bipartite nuclear
localization signal in the amino acid sequence of NOA1 (Fig. 1A).
To analyze whether NOA1 is transported into the nucleus,
different subcellular fractions of HEK293 cells were prepared and
analyzed for the presence of unprocessed and processed NOA1 by
Western blotting. The processed NOA1 protein was exclusively
located in the mitochondrial fraction, which is marked by the
mitochondrial respiratory complex protein Complex I 39 k. In
contrast, we found enrichment of the unprocessed NOA1
precursor protein in the nuclear fraction identified by the presence
of Histone H3. Importantly, the nuclear fraction was free of
mitochondrial contaminations as demonstrated by the absence of
Complex I 39 k signals. Removal of the MTS prevented specific
mitochondrial uptake and resulted in the accumulation of DMTS-
NOA1-Flag in the cytosolic and nuclear fraction. The weak
DMTS-NOA1-Flag signal in the mitochondrial fraction is most
likely due to contamination by nuclear proteins as indicated by the
presence of low amounts of Histone H3 (Fig. 1C). The data
demonstrate that unprocessed NOA1 precursor protein is
abundant in a protein fraction enriched for nuclear proteins while
the processed form after cleavage of the mitochondrial targeting
sequence exclusively resides in mitochondria.
A fraction of endogenous NOA1 protein forms puncta in
the nucleus
Next, we investigated the subcellular distribution of overex-
pressed and endogenous NOA1 protein in different cell lines and
primary myofibers by immunofluorescence. We either used co-
expression of the mitochondrial marker protein Omp25-EGFP or
co-immunostaining with the Tom20 antibody, which both label
the mitochondrial network of cells (Fig. 2A). NOA1-EGFP co-
localized with Tom20 confirming the predominant mitochondrial
localization of NOA1. Interestingly, immunostaining for endoge-
nous NOA1 revealed that a fraction of NOA1 formed puncta that
co-localized with mitochondrial Omp25-EGFP and additional foci
in the nucleus confirming our results from the subcellular
fractionation data (Fig. 1C). To confirm the nuclear localization
of endogenous NOA1 under basal conditions we analyzed freshly
isolated mouse myofibers. Immunofluorescence staining revealed
the presence of endogenous NOA1 in myonuclei while Tom20
was completely absent from myonuclei (Fig. 2B). In contrast, co-
localization of NOA1 and Tom20 was seen in areas enriched in
mitochondria surrounding the myonuclei and throughout the
myofiber (Fig. 2B). In cultured cell lines such as C2C12
mitochondria form a network-like structure (Fig. 2A) while
myofibers contain a highly ordered F-actin cytoskeleton that leads
to an alternating, linear arrangement of mitochondria (Fig. 2B, C).
Newly translated NOA1 precursor accumulates in the
nucleus
Cellular fractionation and immunofluorescence staining re-
vealed that NOA1 is present in two different cellular compart-
ments (i.e. nucleus and mitochondria) although the bulk of the
protein is localized in mitochondria. To investigate whether the
subcellular localization of NOA1 is subject to dynamic regulation
we established an assay system based on the fusion of NOA1 to
EGFP and Flag. We confirmed that transfected NOA1-EGFP and
NOA1-Flag predominantly localize to the mitochondrial com-
partment (Figure S2A in File S1). Next, we screened a library of
pharmacological active compounds (LOPAC, Sigma, LO1280) for
a molecule that might change has the subcellular localization of
NOA1. Each compound of the library was applied to NOA1-
EGFP expressing cells at a concentration of 100 mM, followed by
assessment of the subcellular distribution of EGFP fluorescence
after six hours of incubation. Interestingly, four (flunarizine
dihydrochloride, 5-(N,N-Dimethyl)amiloride hydrochloride, qua-
zinone, trequinsin hydrochloride) out of 1280 screened com-
pounds promoted accumulation of NOA1 in the nucleus (Table S1
in File S1). The most profound effect was induced by flunarizine
(Figure S2B in File S1), which changes cellular Ca2+ homeostasis
by inhibition of Ca2+ channels but also exerts additional dose-
dependent effects. The effect of flunarizine corresponds well to the
known effects of increased intracellular Ca2+, which prevents
nuclear shuttling whereas Ca2+ chelators enhance nuclear
translocation [28]. Additionally, flunarizine has been described
before to induce nuclear translocation of Nrf2 probably by
potential inhibition of nuclear export [29,30]. To analyze whether
flunarizine treatment primarily influences transport of newly
translated precursor protein or causes redistribution of already
existing protein from mitochondria to nuclei, we administered
cycloheximide (CHX) to block translation. CHX alone had no
effects on the localization of NOA1-EGFP in mitochondria (Figure
S2C in File S1). However, concomitant treatment of cells with
flunarizine and CHX abolished nuclear accumulation of NOA1-
EGFP (Figure S2D in File S1) indicating that only newly translated
NOA1 precursor protein still carrying the mitochondrial targeting
sequence is routed into nuclei. Interestingly, nuclear accumulation
of overexpressed NOA1-EGFP resulted in massive increase of
apoptosis after prolonged flunarizine treatment. Accompanying
treatment with CHX prevented cellular apoptosis indicating that
nuclear accumulation of NOA1 but not additional effects of
flunarizine was responsible for the increase in programmed cell
death (Figure S2F in File S1). In a secondary screen, we confirmed
the nuclear accumulation of endogenous NOA1 using selected
LOPAC compounds (Table S1 in File S1). Interestingly, induction
of cell death by NOA1 was dependent on the amount of NOA1
protein trapped in the nucleus since nuclear accumulation of
endogenous NOA1, e.g. by flunarizine treatment of non-
transfected cells, was not sufficient to cause apoptosis (Figure
S2C in File S1). Since previous results indicated that inactivation
of NOA1 protect cells from apoptosis [7], we further analyzed the
relation of nuclear accumulation of NOA1 protein and apoptosis.
Transfection of a Flag-tagged NOA1DMTS construct resulted in
prominent accumulation of NOA in the nucleus completely
abolishing mitochondrial import (Fig. 3A) and induced apoptosis
in 20% of the total cell population as indicated by Annexin V and
propidium iodide staining followed by FACS analysis. Since we
achieved a ,30% transfection efficiency we calculated that ,66%
of all NOA1DMTS expressing cells undergo apoptosis (Fig. 3B).
Induction of apoptosis caused by nuclear accumulation of
NOA1DMTS was efficiently repressed by addition of the pan-
caspase inhibitor Z-VAD-FMK during transfection (Fig. 3B) In
conclusion nuclear accumulation of high levels of NOA1 protein
induces cell death. Such nuclear accumulation can be achieved by
overexpression of NOA1DMTS or by treatment of NOA1-EGFP
expressing cells with flunarizine. It will be interesting to address
the underlying mechanism of these observations in further studies.
Nuclear import of NOA1 is directed by a canonical
nuclear localization signal
NOA1 has a size of 77 kDa, which is too large for passive
diffusion through nuclear pores. Hence, we assumed that nuclear
import is accomplished by the importin system acting in concert
with the NLS in NOA1. To further investigate active nuclear
NOA1 Requires Nuclear Shuttling
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import of NOA1 we established an in vitro nuclear import system
using isolated mouse macrophage (RAW264.7) nuclei and
recombinant mouse NOA1 protein. Immunofluorescence staining
(Fig. 3C) and Western blot analysis (Fig. 3D) revealed that NOA1
is imported and retained in nuclei in in the presence of the nuclear
export blocker leptomycin-B [31]. Addition of non-hydrolyzable
GTPcS instead of GTP, which is required by the importin system,
prevented nuclear import (Fig. 3C). Since GTPcS blocks import
but does not prohibit interaction of the importin machinery with
imported proteins we observed coating of nuclei with NOA1
protein (Fig. 3C). As a consequence, GTPcS-mediated inhibition
of NOA1 import was not detectable by Western blot analysis,
which included proteins bound but not necessarily processed by
the importin machinery. Western blot analysis confirmed that
Figure 1. Unprocessed NOA1 precursor protein is localized in the nucleus. (A) Schematic representation of functional domains of the NOA1
protein and description of constructs used in the study. (B) Western blot analysis of C2C12 cells transfected with a NOA1 expression construct. The
antibody against the C-terminal Flag-epitope detects the unprocessed precursor protein and the shorter processed protein present in mitochondria.
Deletion of the N-terminal mitochondrial targeting sequence (MTS) prevents processing. (C) Subcellular fractionation of HEK293 cells expressing
NOA1-Flag and NOA1DMTS-Flag reveals presence of unprocessed precursor proteins in the nuclear fraction marked by Histone H3 and the processed
mature form in the mitochondrial fraction marked by Complex I 39 k. GAPDH served as marker for the cytosolic fraction.
doi:10.1371/journal.pone.0103141.g001
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equal amounts of NOA1 were used for the GTPcS and the control
experiment (Fig. 3D).
NOA1 localizes to nucleoli and interacts with UBF1 in an
RNA and DNA independent manner
To analyze whether NOA1 localizes to specific sites within
nuclei we performed immunostainings of nuclei located in isolated
mouse skeletal muscle myofibers. Endogenous NOA1 protein was
present within distinct foci of myonuclei, which were identified as
nucleoli based on UBF1 co-staining (Fig. 4A). Similar results were
also obtained in other cell types such as fibroblasts (data not
shown). Quantitative analysis of confocal immunofluorescence
data obtained in NIH 3T3 cells revealed that the major peaks
produced by NOA1-staining co-localized with peaks from UBF1
and fibrillarin, another common marker for nucleoli (Fig. 4B).
Since NOA1 and UBF1 showed a striking co-localization in
nucleoli we tested whether both proteins might interact directly.
Pull-down assays using recombinant NOA1-His6 protein loaded
on Ni-NTA beads and whole cell or nucleoli lysate revealed a
physical interaction of NOA1 and UBF1 (Fig. 4C). To confirm
this finding, we performed co-immunoprecipitation experiments
using antibodies directed against endogenous UBF1. We found
Figure 2. A fraction of endogenous NOA1 is found in the nucleus of C2C12 cells and primary mouse myofibers. (A)
Immunofluorescence staining of NOA1-transfected C2C12 cells. Mitochondria were visualized by antibody staining with the outer mitochondrial
membrane markers Tom20 and Omp-25. Overexpressed NOA1-EGFP mainly localizes in mitochondria as shown by co-localization with the
mitochondrial markers Tom20 and Omp-25. Endogenous NOA1 protein detected with a rabbit polyclonal anti-NOA1 antibody also localizes with
mitochondria although a fraction of NOA1 is present in the nucleus. (B) Mitochondria in primary myofibers show a striped pattern alternating with F-
actin. In primary mouse myofibers endogenous NOA1 presents a striated pattern similar to Tom20 and is also seen in punctae in myonuclei. (C)
Diagram of the alternating F-actin/Phalloidin-FITC and Mitochondria/Tom20-Alexa594 fluorescence intensities shown in (B). The arrow highlights the
analyzed region. Data points were fitted by a line with moving average of 10. Confocal images, scale bars: 10 mm.
doi:10.1371/journal.pone.0103141.g002
Figure 3. NOA1 carries a functional nuclear localization signal mediating GTP dependent active nuclear import. (A)
Immunofluorescence staining of NOA1-transfected C2C12 cells. Wild type NOA1 co-localizes with the mitochondrial marker protein Tom20 while
deletion of the N-terminal MTS causes accumulation of EGFP-tagged NOA1 protein in the nucleus. (B) Overexpression of NOA1DMTS in C2C12 leads
to apoptosis, which is partially rescued by addition of 1 mM pan-caspase inhibitor Z-VAD-FMK. A p-value,0.05 was considered significant. (C) Optical
section of isolated RAW264.7 nuclei stained with an antibody against recombinant NOA1-His6. NOA1 is imported into the nuclei in a GTP-dependent
manner. Import is inhibited by addition of the non-hydrolysable GTP analogue GTPcS to the nuclear import assay. (D) Western Blot analysis of
RAW264.7 nuclei after incubation with NOA1-His6 in nuclear import assays demonstrates equal loading of experiment and control nuclei with
recombinant protein. Scale bars: 10 mm.
doi:10.1371/journal.pone.0103141.g003
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Figure 4. A fraction of NOA1 localizes in the nucleolus and interacts with UBF1. (A) Immunofluorescence staining of endogenous NOA1 in
primary mouse myofibers reveals that a fraction of NOA1 is localized in the nucleolus. (B) Quantitative evaluation of confocal images of NIH 3T3
fibroblasts stained with antibodies against NOA1, UBF1 and Fibrillarin. NOA1 and UBF1 or NOA1 and Fibrillarin are co-localized in the nucleolus.
Moving average smoothing was applied to fit data points into curves. (C) Pull-down assays demonstrating interaction of NOA1 and UBF1.
Recombinant NOA1-His6 protein was loaded on Ni-NTA beads and mixed with whole cell or nucleoli lysates from C2C12 cells to pull down interacting
proteins. (D) Co-immunoprecipitation of NOA1-His6 with endogenous UBF1 from C2C12 lysates. (E) Addition of RNAse H or RNAse A to pull-down
assays increased the efficiency of the interaction between NOA1 and UBF1 while addition of DNAse I had no effect. Scale bars: 10 mm, Zoom scale
bars: 1 mM.
doi:10.1371/journal.pone.0103141.g004
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that UBF1 is present in a complex containing NOA1 and
fibrillarin. No interaction was scored for Tfam and S6 ribosomal
protein, which were used as negative controls (Fig. 4D). Since
NOA1 contains a RNA binding domain, we next asked whether
the interaction between NOA1 and UBF1 requires RNA or DNA.
Addition of RNAses and DNAse to the pull-down assays did not
compromise the interaction between NOA1 and UBF1 but
resulted in a mild increase of UBF1 in pull-down assays, which
might indicate that RNA restricts interaction of NOA1 with UBF1
(Fig 4E). We recently reported that NOA1 binds to G-quadruplex
RNA [32]. Hence, it is tempting to speculate that increased
concentrations of G-quadruplex RNA ligands limit binding of
NOA1 to UBF1.
NOA1 contains a leptomycin-B sensitive nuclear export
signal that mediates nucleo-cytoplasmic shuttling
So far, we demonstrated that the nuclear import of NOA1 is
directed by a canonical nuclear localization signal resulting in
accumulation of NOA1 in nucleoli. To learn more about the
mechanism that are responsible for the export of NOA1 from
nuclei and subsequent import into mitochondria, we asked
whether nuclear export of NOA1 depends on Crm1, which is a
key component of the nuclear export machinery. Since Crm1 is
covalently modified and inactivated by leptomycin-B [31] we
treated C2C12 myoblasts with leptomycin-B. Immunofluores-
cence staining of endogenous NOA1 protein revealed a punctate
pattern (Fig. 2) indicating a strong accumulation of endogenous
NOA1 in nucleoli of C2C2 cells upon nuclear export blockade
(Fig. 5A). Inhibition of nuclear export resulted in a homogenous
distribution of NOA1 signal throughout the cell, which contrasted
to the discrete punctate pattern in the control situation (Fig. 5A).
Similar results were obtained in fibroblasts. Again, the NOA1
protein appeared to be homogeneously distributed throughout the
nucleoplasm and the cytoplasm when nuclear export was blocked
by leptomycin-B treatment (Fig. 5B). Inhibition of transcription by
actinomycin D phenocopied leptomycin-B induced accumulation
of NOA1 in the nucleus and nucleoli suggesting that nuclear
export and subsequent import of NOA1 into mitochondria
requires active transcription (Fig. 5B).
The observation that nuclear export of NOA1 was dependent
on Crm1 prompted us to search for a corresponding putative
nuclear export signal (NES). In fact, we detected a NES motif
positioned in reverse order within the predicted leucine zipper
domain (Fig 5C). EGFP lacking a specific targeting signal is found
in the cytosol and also causes bright fluorescence in the nucleus.
Fusion of the NOA1-NLS to EGFP did not cause dramatic
changes in the distribution of EGFP while addition of the putative
NOA1-NES to NLS-EGFP clearly reduced nuclear fluorescence.
Most likely, the increased nuclear export of NLS-NES-EGFP
compared to NLS-EGFP was responsible for the reduced
accumulation in nuclei (Fig. 5D). Accordingly, treatment of cells
transfected with the NLS-NES-EGFP construct with leptomycin-B
increased EGFP fluorescence in the nucleus confirming function-
ality of the putative NOA1-NES (Fig. 5D).
The RNA binding domain containing C-terminus and
prior nucleolar localization are critical for mitochondrial
import of NOA1
To test whether localization in nucleoli is a prerequisite for
mitochondrial import of NOA1, we mutated the NLS of NOA1
and assessed its subcellular localization and dynamics (Fig 6A). As
expected, wild type NOA1 localized to mitochondria visualized by
Tom20 staining. Mutation of the NLS in full length NOA1
strongly impaired mitochondrial localization and changed the
morphology of mitochondria, which accumulated in a peri-nuclear
position. NOA1 mutants carrying a mutated NLS and lacking the
MTS were found outside the nucleus in the cytosol while lack of
the MTS resulted in a primarily nuclear localization (Fig. 6A).
Next, we quantitatively analyzed localization of WT and NLS
mutant NOA1 proteins. Cells were investigated 24 hours after
transfection to avoid artifacts caused by accumulation of NOA1 in
nuclei (Fig 6B). We distinguished three different localizations of
NOA1: (i) mitochondrial localization; (ii) nuclear localization and
(iii) ‘‘aggregated’’ referring to unclear or mixed subcellular
localization of NOA1 probably caused by compromised mito-
chondrial import. About ,80% of wild type NOA1 localized to
mitochondria and only a minor fraction of 7% were found in the
nucleus, which is in line with the immunostaining for endogenous
NOA1 protein (Fig 4A, 5A). Leptomycin-B treatment of cells
transfected with wild type NOA1 increased concentration in nuclei
to ,33% leaving ,42% of wild type NOA1 in mitochondria
(Fig 6B). Leptomycin-B also increased the aggregated localization
from ,15% to 25% probably based on the cellular stress resulting
from nuclear accumulation of NOA1, which eventually causes
apoptosis (Fig. 3B). As expected the NLS mutant of NOA1 did not
respond to leptomycin-B because it is not imported into the
nucleus. Strikingly, mutation of the NLS severely reduced
mitochondrial localization of NOA1. Only 36% NLS mutant
NOA1 localized to the mitochondrial compartment compared to
,78% wild type NOA1 strongly suggesting that NOA1 needs to
acquire a nuclear localization before mitochondrial import
(Fig. 6B). Addition of a Flag or HA epitope to the C-terminal
end of NOA1 did not interfere with mitochondrial targeting
(Fig 6C) and N-terminal processing of the precursor NOA1
protein (Fig 6D). In contrast, addition of a HA-tag to the N-
terminus prevented mitochondrial import, which is common for
mitochondrial proteins carrying a classical N-terminal targeting
sequence (Fig. 6C, Fig. 6D). Interestingly, deletion of the C-
terminal part of NOA1, which contains the RNA-binding domain,
disrupted correct localization to mitochondria similar to the
NOA1-NLS mutant (Fig 6A). Western blot analysis confirmed
that the MTS of the NOA1-DC-terminus mutant was not fully
processed validating the failure of mitochondrial import when the
RNA-binding domain was absent (Fig. 6E).
Degradation of NOA1 by the mitochondrial matrix
protease ClpXP depends on a C-terminal ClpX
recognition motif
Our data demonstrated dynamic regulation of the subcellular
localization of NOA1 indicating the need for a tight control of
NOA1 in different cellular compartments. To gain further insights
Figure 5. Nuclear export of NOA1 is mediated by a Crm1-dependent Nuclear Export Signal (NES). A) Immunofluorescence staining of
endogenous NOA1 in C2C12 cells. One-hour treatment with 10 ng/ml leptomycin-B leads to accumulation of NOA1 in nuclear foci. (B) Nuclear NOA1
is localizes in distinct foci of UBF1-stained nucleoli and accumulates after leptomycin-B (10 ng/ml) and actinomycin D (1 mg/ml) treatment. (C) Amino
acid sequences of the nuclear export sequence (NES) of different proteins including NOA1. (D) Different cellular targeting sequences of NOA1 direct
cellular localization of EGFP fusion proteins. Leptomycin-B treatment (10 ng/ml) leads to increased accumulation of NLS-NES-EGFP fusion protein in
nucleus. Tom20 staining was used to identify mitochondria. Scale bars: 10 mm, zoom scale bar: 1 mM.
doi:10.1371/journal.pone.0103141.g005
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Figure 6. Nuclear localization and the 25 kDa C-terminus is essential for subsequent mitochondrial import of NOA1. (A)
Immunofluorescence staining of different Flag tagged NOA1 proteins transfected into C2C12 cells reveals requirement of the NLS and the C-terminus
of NOA1 for mitochondrial import. Deletion of the MTS abolishes mitochondrial localization leading to accumulation of NOA1 in the nucleus.
Mutation of the NLS in the DMTS mutant confirms that the NLS is necessary for nuclear localization. Mitochondria were identified by co-staining for
Tom20. (B) Quantitative evaluation of the subcellular dynamics of wild type and mutant NOA1 protein. Wild type NOA1 protein shows a predominant
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into the pathways controlling NOA1 levels in mitochondria, the
main site of NOA1 localization under physiological conditions, we
studied its potential mode of degradation. Although some
exceptions seem to exist, protein turnover within the mitochon-
drial matrix relies mostly on three major matrix proteases: Lon, m-
AAA and ClpXP [33,34]. Interestingly, the C-terminus of NOA1
contains a conserved motif that resembles the ClpX specific
recognition motif C-motif2 found in E. coli substrates [35]
(Fig 7A, B). To test whether turnover of NOA1 in mitochondria
depends on ClpXP we mutated the two lysines in the most
proximal C-motif2 of NOA1 into alanines. Insertion of the K690A
and K691A mutation led to a ,60% increase in NOA1
concentrations compared to wild type indicating stabilization of
the protein (Fig 7C). Although NOA1-KK690,691AA-Flag was
not entirely protected from degradation, the increased stability
indicated that the C-terminal region is recognized by ClpX.
Furthermore, expression of the catalytic subunit ClpX alone in
NOA1 overexpressing cells resulted in a rapid depletion of NOA1
confirming that detection of NOA1 by the ClpX subunit is the
limiting step for proteolytic degradation (Fig. 7D). Since the C-
motif2 is present in the mammalian NOA1 protein and in
prokaryotic substrates of ClpXP we tested whether recombinant
E.coli ClpX and ClpP are able to degrade mammalian NOA1. As
expected, E.coli ClpP alone was unable to reduce the concentra-
tion of NOA1 (Fig. 7E). In contrast, addition of the E.coli ClpXP
complex resulted in a rapid decline of NOA1 levels within 30 min,
clearly establishing NOA1 as a mammalian substrate of the
conserved ClpXP system (Fig 7E). In agreement with previous
reports we found that a-Casein was degraded by mammalian
ClpXP, but not by E. coli ClpXP (Fig. 7E) (Kang et al, 2002). To
reconstitute mammalian ClpXP activity in vitro, we used a
chimeric complex consisting of mouse ClpX and human ClpP.
This chimeric mammalian ClpXP complex was less efficient to
degrade mouse NOA1 compared to E.coli ClpXP (Fig. 7E, F),
which might indicate species specificities and/or indicate the
existence of additional proteins assisting mammalian ClpXP.
Discussion
NOA1 is an essential mitochondrial matrix protein, which
regulates mitochondrial ribosome biogenesis and OXPHOS
activity dependent on its GTPase activity [1,2,4]. Although several
studies have addressed the function of NOA1, information about
the dynamics of its subcellular localization was lacking. The
current report demonstrates that NOA1 contains a functional NLS
and a Crm1 dependent NES, which are responsible for active
nuclear import and export. The NES is localized in a predicted
leucine zipper region required for dimerization or other protein-
protein interactions [1], which might be important for masking the
NES thereby restricting nuclear export. A similar scenario has
been described for the pivotal stress response protein NRF2 [36].
Alternatively, it seems possible that a putative NOA1 ligand or
interaction partner, such the nucleolar protein UBF1, regulates
accessibility of the NES and the nuclear export rate.
NOA1 shows an unusual routing within cells. We are not aware
of a mitochondrial matrix protein that takes a mandatory ’’detour’’
through another cellular compartment before embarking at its
final destination although other proteins are known, which reside
within the nucleus and mitochondria. However, such proteins
including LRPPRC [13,14], ELAC2 [19], CRIF1 (CR-6 inter-
acting protein) [37], TERT [20] and p53 [21] do not necessarily
enter the nucleus before ending up in mitochondria making
NOA1 the founding member of a novel category of ‘‘dual targeted
mitochondrial proteins’’. Since the nuclear form of NOA1 still
contains the mitochondrial targeting sequence, we can exclude a
retrograde mito-nuclear transport. We would also like to stress that
newly translated NOA1 precursor protein accumulates exclusively
in the nucleus when nuclear export is blocked, which clearly
argues for a sequential transport first into the nucleus and then
into mitochondria ruling out the alternative usage of mitochon-
drial and nuclear targeting sequences.
LRPPRC, CRIF1 and NOA1 are predominantly located within
mitochondria while TERT and p53 leave the nucleus mainly
during cellular stress. Interestingly, the nuclear form of the
GADD45 family protein CRIF1 is also involved in the regulation
of cellular stress responses by negative regulation of NRF2 [38]. In
contrast, its mitochondrial form regulates OXPHOS similar to
NOA1 [1,37]. However, some studies aiming at the nuclear
function of CRIF1 were performed using N-terminally tagged
versions of the proteins, which interferes with mitochondrial
targeting increasing nuclear localization [39]. Intriguingly, nuclear
LRPPRC has been reported to be part of a nuclear ribonucleo-
protein complex that contains RNA. NOA1 carries an RNA
binding site that interacts with G-quadruplex RNA [32]. Although
very little is known about the endogenous NOA1 RNA ligand, it is
tempting to speculate that NOA1 binds G-quadruplex RNA,
which is highly abundant in the nucleolus. RNAse treatment
resulted in a mild increase of UBF1-NOA1 interactions, which
might indicate that RNA binding facilitates release of NOA1 from
the nucleolar protein complex. Another hint for the relevance of
binding of NOA1 to RNA in the nucleolus was the effect of
actinomycin D, which retained NOA1 in the nucleus similar to the
nuclear export blocker leptomycin-B. This observation supports
the idea that release of NOA1 from the nucleolus might depend on
newly transcribed RNA ligands, although we presently lack firm
evidence for such a mechanism. Under any circumstances, the
alternative localization of NOA1 might indicate different functions
in the nucleus versus mitochondria, affect bioavailability in each
compartment or allow communication between both organelles.
The finding that the mitochondrial matrix protease complex
ClpXP mediates degradation of NOA1 further supports our model
of a unidirectional nucleo-mitochondrial pathway (Fig. 8). Once
NOA1 reaches its final destination, the mitochondrial matrix, it
will be degraded on-site by ClpXP after fulfilling its role as a
regulator of mitochondrial protein synthesis and OXPHOS. We
reason that similar nucleo-mitochondrial transport pathways
might also be employed by LRPPRC, CRIF1 and other proteins,
which have not been studied in this respect. In case of NOA1,
disruption of the nucleo-mitochondrial transport pathway is
detrimental for the cell. Accumulation of NOA1 in the nucleus
presents a strong trigger for apoptosis, which can be blocked by
pan-caspase inhibitors. Further studies will show whether this
‘‘Mitochondrial’’ localization. DMTS-NOA1 shows a predominant ‘‘nucleus’’ accumulation. NOA1-NLS mutants show a mixed localization as indicated
by the term ‘‘aggregated’’. Wild type NOA1 is dynamically distributed between nucleus and mitochondria. Leptomycin-B treatment prevents nuclear
export and subsequent mitochondrial import of wild type NOA1. Mutation of the NLS prevents nuclear accumulation of NOA1 after leptomycin-B
treatment. (C) N-terminal tagging prevents import of NOA1 into mitochondria of NIH 3T3 cells by masking the MTS. (D) A Western blot analysis of N-
terminally (HA tag) and C-terminally (Flag tag) modified versions of NOA2 is shown. (E) Deletion of the RNA-binding domain containing C-terminus
prevents mitochondrial import in NIH 3T3 cells. Western blot analysis demonstrated strongly reduced processing of the MTS after truncation of the C-
terminus. Scale bars: 10 mm.
doi:10.1371/journal.pone.0103141.g006
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Figure 7. NOA1 is a substrate of the mitochondrial matrix protease complex ClpXP. (A) The C-terminus of NOA1 contains three motifs
resembling known ClpX recognition motifs found in proteins of E.coli. (B) Exemplary Western blot analysis revealing increased concentrations of
NOA1 in C2C12 cells after mutation of lysin690 and lysin691 to alanines in the proximal ClpX recognition motif. (C) Quantitative analysis of Western
blots demonstrating ca. 60% stabilization of the NOA1-KK690,691AA mutant compared to wild type NOA1. Densitometries from three independent
experiments were normalized to Porin. (D) Overexpression of ClpX is sufficient to promote degradation of NOA1 independent of a C-terminal Flag tag
in C2C12 cell lysates. (E) Recombinant bacterial ClpXP (E.coli ClpXP) (top left) and mammalian ClpXP (mouse ClpX, human ClpP) (top right) cleaves
recombinant NOA1 (2.5 mM) in vitro in a time dependent manner. Mammalian ClpXP but not by E. coli ClpXP cleaves a-Casein (5 mM) in vitro. (F)
Quantitation analysis of Western blots shown in (E) demonstrating the degradation of NOA1 by bacterial and mammalian ClpXP in vitro.
doi:10.1371/journal.pone.0103141.g007
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novel means of induction of apoptosis is used by the cell under
pathophysiological conditions, e.g. by actively blocking export of
NOA1 from the nucleus.
Supporting Information
File S1 Supporting table and figures. Table S1, Screening
of nuclear compounds initiating nuclear accumulation of NOA1.
A panel of 1280 compounds (LOPAC1280 panel, Sigma Aldrich)
was screened for factors causing accumulation of NOA1 in nuclei
of C2C12 cells. The primary screen for compounds was evaluated
by analysis of nuclear fluorescence caused by transfected NOA1-
EGFP six hours after treatment with 100 mM concentrated
substance in DMSO. 3.2% (41/1280) of the compounds induced
increased nuclear accumulation of NOA1. 30.08% (385/1280) of
the compounds induced cell death at a concentration of 100 mM.
Substances causing severe toxic effects on C2C12 cells were
excluded. Effects of compounds were compared to negative
controls (1% DMSO and water), which did have no effects on the
subcellular localization of NOA1-EGFP. All 41 compounds that
were testing positive were subjected to a secondary screen based
on the accumulation of endogenous NOA1 in nuclei of C2C12
cells. 17 out of 41 (1.33% of total) retested compounds consistently
initiated accumulation of endogenous NOA1 in the nucleus of
more than 10% of the cells. Four substances (trequinsine,
quazinone, flunarizine and amiloride) were further analyzed.
Flunarizine yielded the strongest effects and was therefore
employed for subsequent studies. Figure S1, Rabbit polyclonal
anti-NOA1 antibody is specific for precursor and mature NOA1
protein. To assess specificity of the rabbit polyclonal anti-NOA1
antibody used in this study we expressed C-terminally Flag tagged
NOA1 in C2C12 myoblasts and analyzed the protein lysates by
Western blotting. Flag antibody detected the larger precursor and
the shorter, mature, N-terminally processed NOA1 protein.
Similar result was obtained with the antibody raised against
NOA1. Although highly specific, the endogenous NOA1 protein
expression was below threshold for detection by Western blot.
Figure S2, Flunarizine induces accumulation of NOA1 in the
nucleus. (A) Immunofluorescence staining of NOA1-transfected
C2C12 cells. NOA1 mainly localizes in mitochondria as
demonstrated by co-localization with the mitochondrial marker
protein Tom20. (B) Six hour treatment with flunarizine (100 mM),
identified by screening a LOPAC library for compounds altering
subcellular localization of NOA1, leads to rapid accumulation of
NOA1-EGFP in the nucleus of C2C12 cells. (C) FACS analysis of
non-transfected C2C12 cells after Flunarizine treatment (100 mM
for 6 hours) shows no increase of apoptosis. (D) Inhibition of
translation by 10 ng/ml Cycloheximide (CHX) does not affect
mitochondrial localization of NOA1-EGFP. (E) Combined
treatment with Flunarizine (100 mM) and CHX (10 ng/ml)
prevents accumulation of NOA1 in the nucleus indicating that
only newly translated NOA1 is targeted to the nucleus. (F)
Combined CHX and flunarizine treatment of NOA1-EGFP
transfected C2C12 cells reduces the percentage of NOA1-EGFP
positive non-viable cells compared to flunarizine treatment alone.
Cell viability was assessed by counting the number of attached and
non-rounded EGFP-positive cells. Scale bars: 10 mm.
(PDF)
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